Molecular detection of cancer cells by competitive reverse transcription-polymerase chain reaction analysis of specific CD44 variant RNAs

Isamu Okamoto, Tetsuro Morisaki, Ji Ichiro Sasaki, Hideaki Miyake, Mitsuhiro Matsumoto, Moritaka Suga, Masayuki Ando, Hideyuki Saya

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Background: CD44 is a cell surface glycoprotein implicated in such diverse biologic processes as lymphocyte activation and homing, extracellular matrix adhesion, and cellular migration. Primary transcripts of the CD44 gene can be alternatively spliced to produce a variety of messenger RNA (mRNA) species. The standard form of CD44 mRNA contains sequences from at least 20 genomic exons; variant mRNAs contain sequences from one or more additional exons (v1-10). Predominant expression of a specific CD44 variant, i.e., CD44v8-10, in several human carcinomas has been described previously. In this study, we developed a novel molecular approach for detecting cancer cells that overexpress CD44v8-10 mRNA. Methods: After finding that CD44v8-10 was predominantly expressed in non-small-cell lung and bladder carcinomas and that CD44v10 was predominantly expressed in leukocytes, we developed a competitive reverse transcription-polymerase chain reaction assay (CC-RT- PCR) that allows quantification of the relative expression of these two mRNA species in clinical specimens (i.e., determination of a v8-10/v10 ratio). CC- RT-PCR analysis was applied to pleural effusion specimens from patients with benign or malignant lung diseases as well as to spontaneously voided urine samples from patients with benign or malignant urologic diseases. Results: Fifty two of 54 samples from patients with benign diseases expressed CD44v10 predominantly (v8-10/v10 ratio ≤0.65), whereas 46 of 61 samples from patients with malignant diseases expressed CD44v8-10 predominantly (v8- 10/v10 ratio >1.00) (two-sided P<.001). CC-RT-PCR detected predominant expression of CD44v8-10 in cytologically negative samples from 11 patients who were later diagnosed with malignant disease. Conclusions: CC-RT-PCR analysis of CD44v8-10 expression could be an important adjunct to cytologic examination in cancer diagnosis, especially in detecting exfoliated cancer cells in pleural effusions and urine.

Original languageEnglish
Pages (from-to)307-315
Number of pages9
JournalJournal of the National Cancer Institute
Volume90
Issue number4
DOIs
Publication statusPublished - Feb 18 1998

Fingerprint

Reverse Transcription
RNA
Polymerase Chain Reaction
Messenger RNA
Pleural Effusion
Neoplasms
Exons
Urine
Urologic Diseases
Membrane Glycoproteins
Lymphocyte Activation
Non-Small Cell Lung Carcinoma
Lung Diseases
Extracellular Matrix
Urinary Bladder
Leukocytes
Carcinoma
Genes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Molecular detection of cancer cells by competitive reverse transcription-polymerase chain reaction analysis of specific CD44 variant RNAs. / Okamoto, Isamu; Morisaki, Tetsuro; Sasaki, Ji Ichiro; Miyake, Hideaki; Matsumoto, Mitsuhiro; Suga, Moritaka; Ando, Masayuki; Saya, Hideyuki.

In: Journal of the National Cancer Institute, Vol. 90, No. 4, 18.02.1998, p. 307-315.

Research output: Contribution to journalArticle

Okamoto, Isamu ; Morisaki, Tetsuro ; Sasaki, Ji Ichiro ; Miyake, Hideaki ; Matsumoto, Mitsuhiro ; Suga, Moritaka ; Ando, Masayuki ; Saya, Hideyuki. / Molecular detection of cancer cells by competitive reverse transcription-polymerase chain reaction analysis of specific CD44 variant RNAs. In: Journal of the National Cancer Institute. 1998 ; Vol. 90, No. 4. pp. 307-315.
@article{df1b45fcfad54525bcbf796b9d5ea728,
title = "Molecular detection of cancer cells by competitive reverse transcription-polymerase chain reaction analysis of specific CD44 variant RNAs",
abstract = "Background: CD44 is a cell surface glycoprotein implicated in such diverse biologic processes as lymphocyte activation and homing, extracellular matrix adhesion, and cellular migration. Primary transcripts of the CD44 gene can be alternatively spliced to produce a variety of messenger RNA (mRNA) species. The standard form of CD44 mRNA contains sequences from at least 20 genomic exons; variant mRNAs contain sequences from one or more additional exons (v1-10). Predominant expression of a specific CD44 variant, i.e., CD44v8-10, in several human carcinomas has been described previously. In this study, we developed a novel molecular approach for detecting cancer cells that overexpress CD44v8-10 mRNA. Methods: After finding that CD44v8-10 was predominantly expressed in non-small-cell lung and bladder carcinomas and that CD44v10 was predominantly expressed in leukocytes, we developed a competitive reverse transcription-polymerase chain reaction assay (CC-RT- PCR) that allows quantification of the relative expression of these two mRNA species in clinical specimens (i.e., determination of a v8-10/v10 ratio). CC- RT-PCR analysis was applied to pleural effusion specimens from patients with benign or malignant lung diseases as well as to spontaneously voided urine samples from patients with benign or malignant urologic diseases. Results: Fifty two of 54 samples from patients with benign diseases expressed CD44v10 predominantly (v8-10/v10 ratio ≤0.65), whereas 46 of 61 samples from patients with malignant diseases expressed CD44v8-10 predominantly (v8- 10/v10 ratio >1.00) (two-sided P<.001). CC-RT-PCR detected predominant expression of CD44v8-10 in cytologically negative samples from 11 patients who were later diagnosed with malignant disease. Conclusions: CC-RT-PCR analysis of CD44v8-10 expression could be an important adjunct to cytologic examination in cancer diagnosis, especially in detecting exfoliated cancer cells in pleural effusions and urine.",
author = "Isamu Okamoto and Tetsuro Morisaki and Sasaki, {Ji Ichiro} and Hideaki Miyake and Mitsuhiro Matsumoto and Moritaka Suga and Masayuki Ando and Hideyuki Saya",
year = "1998",
month = "2",
day = "18",
doi = "10.1093/jnci/90.4.307",
language = "English",
volume = "90",
pages = "307--315",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Molecular detection of cancer cells by competitive reverse transcription-polymerase chain reaction analysis of specific CD44 variant RNAs

AU - Okamoto, Isamu

AU - Morisaki, Tetsuro

AU - Sasaki, Ji Ichiro

AU - Miyake, Hideaki

AU - Matsumoto, Mitsuhiro

AU - Suga, Moritaka

AU - Ando, Masayuki

AU - Saya, Hideyuki

PY - 1998/2/18

Y1 - 1998/2/18

N2 - Background: CD44 is a cell surface glycoprotein implicated in such diverse biologic processes as lymphocyte activation and homing, extracellular matrix adhesion, and cellular migration. Primary transcripts of the CD44 gene can be alternatively spliced to produce a variety of messenger RNA (mRNA) species. The standard form of CD44 mRNA contains sequences from at least 20 genomic exons; variant mRNAs contain sequences from one or more additional exons (v1-10). Predominant expression of a specific CD44 variant, i.e., CD44v8-10, in several human carcinomas has been described previously. In this study, we developed a novel molecular approach for detecting cancer cells that overexpress CD44v8-10 mRNA. Methods: After finding that CD44v8-10 was predominantly expressed in non-small-cell lung and bladder carcinomas and that CD44v10 was predominantly expressed in leukocytes, we developed a competitive reverse transcription-polymerase chain reaction assay (CC-RT- PCR) that allows quantification of the relative expression of these two mRNA species in clinical specimens (i.e., determination of a v8-10/v10 ratio). CC- RT-PCR analysis was applied to pleural effusion specimens from patients with benign or malignant lung diseases as well as to spontaneously voided urine samples from patients with benign or malignant urologic diseases. Results: Fifty two of 54 samples from patients with benign diseases expressed CD44v10 predominantly (v8-10/v10 ratio ≤0.65), whereas 46 of 61 samples from patients with malignant diseases expressed CD44v8-10 predominantly (v8- 10/v10 ratio >1.00) (two-sided P<.001). CC-RT-PCR detected predominant expression of CD44v8-10 in cytologically negative samples from 11 patients who were later diagnosed with malignant disease. Conclusions: CC-RT-PCR analysis of CD44v8-10 expression could be an important adjunct to cytologic examination in cancer diagnosis, especially in detecting exfoliated cancer cells in pleural effusions and urine.

AB - Background: CD44 is a cell surface glycoprotein implicated in such diverse biologic processes as lymphocyte activation and homing, extracellular matrix adhesion, and cellular migration. Primary transcripts of the CD44 gene can be alternatively spliced to produce a variety of messenger RNA (mRNA) species. The standard form of CD44 mRNA contains sequences from at least 20 genomic exons; variant mRNAs contain sequences from one or more additional exons (v1-10). Predominant expression of a specific CD44 variant, i.e., CD44v8-10, in several human carcinomas has been described previously. In this study, we developed a novel molecular approach for detecting cancer cells that overexpress CD44v8-10 mRNA. Methods: After finding that CD44v8-10 was predominantly expressed in non-small-cell lung and bladder carcinomas and that CD44v10 was predominantly expressed in leukocytes, we developed a competitive reverse transcription-polymerase chain reaction assay (CC-RT- PCR) that allows quantification of the relative expression of these two mRNA species in clinical specimens (i.e., determination of a v8-10/v10 ratio). CC- RT-PCR analysis was applied to pleural effusion specimens from patients with benign or malignant lung diseases as well as to spontaneously voided urine samples from patients with benign or malignant urologic diseases. Results: Fifty two of 54 samples from patients with benign diseases expressed CD44v10 predominantly (v8-10/v10 ratio ≤0.65), whereas 46 of 61 samples from patients with malignant diseases expressed CD44v8-10 predominantly (v8- 10/v10 ratio >1.00) (two-sided P<.001). CC-RT-PCR detected predominant expression of CD44v8-10 in cytologically negative samples from 11 patients who were later diagnosed with malignant disease. Conclusions: CC-RT-PCR analysis of CD44v8-10 expression could be an important adjunct to cytologic examination in cancer diagnosis, especially in detecting exfoliated cancer cells in pleural effusions and urine.

UR - http://www.scopus.com/inward/record.url?scp=0032542497&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032542497&partnerID=8YFLogxK

U2 - 10.1093/jnci/90.4.307

DO - 10.1093/jnci/90.4.307

M3 - Article

C2 - 9486817

AN - SCOPUS:0032542497

VL - 90

SP - 307

EP - 315

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 4

ER -